菜单

Scientific Poster Download

From Target to Trial: Agile GMP Protein Supply for Accelerated Immuno-Radiopharmaceuticals
Shurong Xu, Chengqi Qiu, Huilin Zhu, Kewei Yang
Clinical Manufacturing Department, WuXi Biologics; US and EU CMC Management Department, WuXi Biologics

With the advent of precision medicine, radionuclide-based tumor-targeted imaging and therapy hold great promise for accurate diagnosis and treatment. Antibody-based radiopharmaceuticals can precisely deliver radionuclides to tumor sites, maximizing radiation to tumors while minimizing toxicity to healthy tissues. The biological targeting moiety—such as an antibody or VHH—acts as the core engine, determining specificity, binding affinity, tumor uptake, and overall therapeutic efficacy and safety. This precision enables technologies like immuno-PET and advanced radioligand therapies.

 

However, a major bottleneck remains: the rapid and cost-effective production of high-quality, GMP-grade targeting proteins. Overcoming this challenge is critical to accelerating clinical translation. This poster presents WuXi Biologics’ strategies to reduce cost and timelines in producing biological targeting modalities—without compromising product quality.

Discuss This Poster

To discuss the data in this poster, please complete the form on the following page to connect with our experts.

Connect with our Experts